A Multi-center, Open, One-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of T00660AA for the Treatment of Endometriosis Over 52 Weeks (Follow-up to Study 307041) [EXTENSION OF 700008124]
Latest Information Update: 30 Jan 2014
At a glance
- Drugs Dienogest (Primary)
- Indications Endometriosis
- Focus Adverse reactions; Registrational
- Sponsors Bayer
- 17 Jan 2013 New trial record